Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00348686 |
The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.
Condition | Intervention | Phase |
---|---|---|
Hypertension Left Ventricular Hypertrophy |
Drug: Candesartan Drug: Felodipine Procedure: Study manual adherence |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | A Multicenter, Non-Comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy |
Enrollment: | 315 |
Study Start Date: | June 2006 |
Study Completion Date: | October 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Korea, Republic of | |
Research Site | |
DaeGu, Korea, Republic of | |
Research Site | |
BuSan, Korea, Republic of | |
Research Site | |
KwangJu, Korea, Republic of | |
Research Site | |
JeonJu, Korea, Republic of | |
Research Site | |
DaeJeon, Korea, Republic of | |
Research Site | |
ULSAN, Korea, Republic of | |
Research Site | |
CheongJu, Korea, Republic of | |
Research Site | |
Chunbuk, Korea, Republic of | |
Research Site | |
GYUNGSANGNAMDO, Korea, Republic of | |
Research Site | |
PUSAN, Korea, Republic of | |
Research Site | |
CheonAn, Korea, Republic of |
Study Director: | JeeWoong Son, MD | AstraZeneca |
Study ID Numbers: | D2452L00012, CAP |
Study First Received: | July 3, 2006 |
Last Updated: | October 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00348686 |
Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
LVH |
Candesartan cilexetil Pathological Conditions, Anatomical Calcium, Dietary Hypertrophy, Left Ventricular Hypertrophy Heart Diseases |
Candesartan Vascular Diseases Angiotensin II Cardiomegaly Felodipine Hypertension |
Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Vasodilator Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Calcium Channel Blockers |
Cardiovascular Diseases Cardiovascular Agents Anti-Arrhythmia Agents Antihypertensive Agents Pharmacologic Actions |